HONG KONG, Feb 24, 2020 - (ACN Newswire) - Aptorum Group
Limited ("Aptorum Group"), a pharmaceutical company focused on the
development of novel therapeutics to address global unmet medical
needs, announces the commercialization of its dietary supplement
for women undergoing menopause and experiencing related symptoms.
The supplement is made with the bioactive ingredient extracted
Chinese yam powder containing "DOI", which is Aptorum Group's
non-hormonal approach intended to meet certain growing consumer
nutritional trends and concerns. It is estimated that 1.2 billion
women worldwide will be menopausal or postmenopausal by the year
20301. The global woman's health supplement market for menopausal
symptoms is projected to reach over USD$50bn by 2025 with a CAGR
rate of 16.4% (2016-2025)2. Initially, the supplement will be
commercialized and sold in Hong Kong; the Company is seeking
regulatory clearance to market the product in other major
jurisdictions.
As part of the commercialization, Aptorum Group, through its
wholly-owned subsidiary Nativus Life Sciences Limited, entered into
a regional distribution agreement with Multipak Limited, a Hong
Kong based group that operates household brands, including the Luk
Yu tea bag and other health related products.
Through Multipak, Aptorum Group will be able to increase the
accessibility of the product to a large consumer base regionally.
The production of Aptorum Group's dioscorea opposita bioactive
nutraceutical tablets has commenced production in Canada and will
soon be marketed under the brand name NativusWellTM.
Nativus's NativusWellTM tablets are natural, non-hormonal
supplements containing DOI. The yam powder with DOI utilizes a
non-hormonal approach that is intended to boost the general
wellness of women undergoing menopause. Third party scientific
studies indicate that DOI, the naturally occurring bioactive
ingredient in Chinese yam, appears to stimulate estradiol
biosynthesis, induce estradiol and progesterone secretion and
increase bone density, thereby potentially counteracting the
progression of osteoporosis3, one of the common symptoms associated
with menopause4.
For further general presentation, please visit:
http://ir.aptorumgroup.com/static-files/bcf77574-7bd6-4b9d-8110-d53837238f16
For further technical presentation, please visit:
http://ir.aptorumgroup.com/static-files/66346f79-7a03-474a-89be-0eaafaa00d9d
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company
dedicated to developing and commercializing novel therapeutics to
tackle unmet medical needs. Aptorum Group is pursuing therapeutic
projects in orphan diseases, infectious diseases, metabolic
diseases and other disease areas.
For more information about Aptorum Group, please visit
www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as "may," "should," "expects," "plans," "anticipates,"
"could," "intends," "target," "projects," "contemplates,"
"believes," "estimates," "predicts," "potential," or "continue," or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the company's
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group's Form 20-F and other filings that Aptorum Group may make
with the SEC in the future. As a result, the projections included
in such forward-looking statements are subject to change. Aptorum
Group assumes no obligation to update any forward-looking
statements contained in this press release as a result of new
information, future events or otherwise.
1 World Health Technical Report Series. Research on the Menopause
in the 1990's. Geneva, Switzerland: World Health Organization;
1996.
2
https://www.grandviewresearch.com/press-release/global-isoflavones-market
3
https://www.ke.hku.hk/story/innovation/the-magic-of-chinese-yam-for-treatment-of-menopausal-syndrome;
see also, Scientific Reports, 5-10179.
4
https://www.everydayhealth.com/menopause/osteoporosis-and-menopause.aspx
Contacts
Investors:
Tel: +852 2117 6611
Email: investor.relations@aptorumgroup.com
Media:
Tel: + 852 2117 6611
Email: info@aptorumgroup.com
Source: Aptorum Group Limited
Copyright 2020 ACN Newswire . All rights reserved. |